Comparative Pharmacology
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus TERAZOL 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus TERAZOL 7.
GYNE-LOTRIMIN 3 vs TERAZOL 7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Terconazole is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the enzyme lanosterol 14α-demethylase. This disruption increases membrane permeability and leads to fungal cell death.
Intravaginal: one applicatorful (5 g of 2% cream) or one suppository (200 mg) once daily at bedtime for 3 days.
Intravaginal: One full applicator (approximately 5 g of cream containing 40 mg of terconazole) inserted vaginally once daily at bedtime for 7 consecutive days.
None Documented
None Documented
Terminal elimination half-life is 3.5–5 hours for topical administration; systemic absorption is minimal (<0.5%), so half-life reflects local clearance.
Terminal elimination half-life is approximately 7-10 hours; clinically, it allows for once-daily vaginal application, but systemic accumulation is minimal with vaginal dosing.
Clotrimazole is primarily excreted via feces (biliary elimination) as metabolites, with approximately 0.5% excreted renally as unchanged drug.
Primarily fecal (approximately 60%) as unchanged drug and metabolites; renal excretion accounts for about 20% (mostly metabolites).
Category C
Category C
Azole Antifungal
Azole Antifungal